NCT04216017 is a Phase 2 clinical trial of kenalog in Humeral Fractures, sponsored by University of Washington.

Who is sponsoring NCT04216017?

NCT04216017 is sponsored by University of Washington.

What drugs are being tested in NCT04216017?

Interventions in NCT04216017: kenalog, Lidocaine.

What condition does NCT04216017 study?

NCT04216017 studies Humeral Fractures.

Is NCT04216017 still recruiting?

NCT04216017 is currently completed. Last updated 26 September 2023.

Are results published for NCT04216017?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-26 · How we verify

NCT04216017

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glenohumeral Cortisone Injection

Completed Phase 2 Results posted Last updated 26 September 2023

What this trial tests

Phase 2 trial testing kenalog in Humeral Fractures in 9 participants. Completed in 1 May 2022.

Timeline

1 January 2020

Primary endpoint
1 April 2022

1 May 2022

Quick facts

Lead sponsor	University of Washington
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	9
Start date	1 January 2020
Primary completion	1 April 2022
Estimated completion	1 May 2022
Sites	1 location across United States

Drugs / interventions tested

kenalog — full drug profile →
Lidocaine — full drug profile →

Conditions studied

Humeral Fractures — all drugs for Humeral Fractures →

Sponsor

University of Washington

Who can join

Adults 18 to 90, any sex, with Humeral Fractures. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

American Shoulder Elbow Society Score Primary · 24 weeks

Outcome Instrument high is good low is bad 0-100 The ASES is a condition-specific scale that is intended to measure functional limitations and pain of the shoulder.

Group	Value	95% CI
Controls	46	± 20
Cases	87	± 8

Visual Analogue Scale Secondary · 24 weeks

pain scale - high is bad - low is good 0-100

Group	Value	95% CI
Controls	4	± 3.7
Cases	1	± 0.8

Sponsor's own description

The objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Humeral Fractures

Currently open trials in the same condition.

NCT03796572 — Regional Blocks for Lateral Condyle Fractures · Phase 4 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04216017 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing